The Latest Breaking News from Wedbush

Growing concerns about the safety of bank deposits have prompted investors to approach community and regional banks with caution

The pressure is increasing on the Californian bank, which continues to repeat that it has enough liquidity.

Apellis Pharmaceuticals’ (APLS) stock has jumped more than 25% year-to-date based on FDA approval for treating geographic atrophy. Despite the breakthrough, the company’s ability to scale up production remains a concern. Moreover, its closest competitor is also close to getting approval. Given its poor financials, stretched valuation, and weak profitability,…

Tech companies are racing to figure out how to implement A.I. in their products, and it’s not just about search engines.

The billionaire entrepreneur said it’s unlikely he’ll be able to choose a suitable successor to run the ailing social media platform until the end of 2023.

Tesla stock advanced for eight straight days and gained 68% on the year until Friday. Analysts are signaling the run could end.

"Activism is clearly now circling the Salesforce name in droves ... creating a 'perfect storm' for CEO Marc Benioff," said Wedbush analyst Dan Ives.

Tesla marched higher as data Wednesday shows 59% of its China-made vehicles in January were exported.

Tesla has gained 91% since Jan. 6 bear-market lows, but this Tesla bull just hiked his stock price target.

“There is a window of opportunity to gain share...and 2023 is a pivotal year that will establish the winners and losers in this EV landscape,” Wedbush tech analyst Dan Ives says amid the industry's price cuts.

"The upcoming call and guidance commentary (will be) one of the most important moments in the history of Tesla and for Elon Musk himself," said Wedbush analyst Dan Ives.